Madison biotech company happy to ride the coattails of competitor, By Steve Clark

Madison, WI based Quintessence Biosciences is developing a cancer therapy that targets cancer cell RNA.  Since current cancer therapies target DNA or proteins,  this is a very novel approach to treating cancer.  While Quintessence plans to enter initial clinical trials this summer, its major East Coast competitor, Alfacell, has just finished its second Phase III trial on a similar product.  Read my column, Biotech Takes, to find out why Quintessence is enthusiastic about Alfacell's success.